Lv5
988 积分 2023-05-10 加入
Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation
1天前
待确认
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
1个月前
已完结
Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines
2个月前
已完结
Systemic Light Chain Amyloidosis
2个月前
已关闭
Systemic Light Chain Amyloidosis
2个月前
已关闭
Zevorcabtagene Autoleucel: First Approval
3个月前
已完结
Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study
3个月前
已完结
Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma
3个月前
已完结
Development and validation of an individualized and weighted Myeloma Prognostic Score System (MPSS) in patients with newly diagnosed multiple myeloma
4个月前
已完结
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
5个月前
已完结
皖公网安备34019202002308
